Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 162

Sort by

Sort Order Select

Journal Articles

Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?

Blood (2023) 142 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2023-179460

Published: 2023

Journal Articles

Reappearance of CXCR4 dim /CD5 bright Proliferative Fraction Associates with BTK Mutations and Anticipates Progression in Ibrutinib-Treated CLL

Blood (2023) 142 (Supplement 1): 4627.

https://doi.org/10.1182/blood-2023-174906

Published: 2023

Journal Articles

Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

Blood (2023) 142 (Supplement 1): 3283.

https://doi.org/10.1182/blood-2023-180955

Published: 2023

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

Ibrutinib As First Line Therapy in Chronic Lymphocytic Leukemia Patients over 80 Years Old: A Retrospective Real-Life Multicenter Italian Cohort

Blood (2023) 142 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2023-186479

Published: 2023

Journal Articles

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients into Novel Categories with Different Risk of Early Treatment

Blood (2023) 142 (Supplement 1): 1892.

https://doi.org/10.1182/blood-2023-177884

Published: 2023

Journal Articles

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Blood (2023) 142 (Supplement 1): 6521.

https://doi.org/10.1182/blood-2023-174603

Published: 2023

Journal Articles

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2023-181731

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Blood (2023) 142 (Supplement 1): 6545.

https://doi.org/10.1182/blood-2023-188941

Published: 2023

Journal Articles

Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Blood (2023) 142 (Supplement 1): 6529.

https://doi.org/10.1182/blood-2023-181037

Published: 2023

Journal Articles

Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

Blood (2023) 142 (Supplement 1): 7067.

https://doi.org/10.1182/blood-2023-187545

Published: 2023

Journal Articles

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Blood (2023) 142 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2023-186182

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

CXCR4 Loss Reduces the Local Growth of Richter Syndrome Murine and Patient-Derived Xenograft Models and Impairs BCR and VLA-4 Activation

Claudio Martines, Supriya Chakraborty, Antonella Zucchetto, Erika Tissino, Vincenzo Guastafierro, Marija Vujovikj, Tiziana Vaisitti, Silvia Deaglio, Luca Laurenti, Aleksandar J Dimovski, Valter Gattei, Dimitar G Efremov

Blood (2023) 142 (Supplement 1): 80.

https://doi.org/10.1182/blood-2023-179183

Published: 2023

Journal Articles

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Blood (2022) 140 (22): 2348–2357.

https://doi.org/10.1182/blood.2022016901

Published: 2022

Includes: Supplemental data

Journal Articles

Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo

Claudio Martines, Supriya Chakraborty, Marija Vujovikj, Stefania Gobessi, Tiziana Vaisitti, Silvia Deaglio, Luca Laurenti, Aleksandar J. Dimovski, Dimitar G. Efremov

Blood (2022) 140 (22): 2335–2347.

https://doi.org/10.1182/blood.2022016272

Published: 2022

Includes: Supplemental data

Journal Articles

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Andrea Visentin, Lydia Scarfò, Thomas Chatzikonstantinou, Anargyros Kapetanakis, Christos Demosthenous, Georgios Karakatsoulis, Martin Andres, Darko Antic, David Allsup, Mónica Baile, Dominique Bron, Antonella Capasso, Mark Catherwood, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Julio Delgado, Maria Dimou, Michael Doubek, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Efstathopoulou, El-Ashwah Shimaa, Alicia Enrico, Lucia Farina, Angela Ferrari, Myriam Foglietta, Moritz Furstenau, Jose A. Garcia-Marco, Massimo Gentile, Eva Gimeno, Gomes da Silva Maria, Odit Gutwein, Yervand Hakobyan, Yair Herishanu, jose Angel Hernandez, Tobias Herold, Sunil Iyengar, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Olga Kalashnikova, Elzbieta Kalicinska, Arnon P. Kater, Sabina Kersting, Jorge Labrador, Deepesh Lad, Luca Laurenti, Mark-David Levin, Enrico Lista, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet Palomanes, Mattias Mattsson, Francesca Romana Mauro, Carlota Mayor-Bastida, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Ivana Milosevic, Fatima Miras Calvo, Carsten Utoft Niemann, Jacopo Olivieri, Lorella Orsucci, Maria Papaioannou, Miguel Arturo Pavlovsky, Inga S. Piskunova, Barbara Pocali, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Doreen te Raa, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Amit Shrestha, Martin Šimkovič, Martin Špaček, Paolo Sportoletti, Oana Stanca Ciocan, Tamar Tadmor, Elisabeth Vandenberghe, Marzia Varettoni, Candida Vitale, Ellen Van Der Spek, Michel Van Gelder, Ewa Wasik-Szczepanek, Lucrecia Yáñez, Mohamed A Yassin, Marta Coscia, Barbara Eichhorst, Alessandro Rambaldi, Niki Stavroyianni, Livio Trentin, Kostas Stamatopoulos, Paolo Ghia

Blood (2022) 140 (Supplement 1): 2333–2337.

https://doi.org/10.1182/blood-2022-163259

Published: 2022

Journal Articles

Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfò, Vladimir Otasevic, Nina Rajovic, David Allsup, Alejandro Alonso Cabrero, Martin Andres, Monica Baile Gonzales, Antonella Capasso, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Juan Gonzalo Correa, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Shaimaa El-Ashwah, Alicia Enrico, Blanca Espinet, Lucia Farina, Angela Ferrari, Myriam Foglietta, Alberto Lopez-Garcia, Jose A. Garcia-Marco, Rocío García-Serra, Massimo Gentile, Eva Gimeno, Maria Gomes da Silva, Odit Gutwein, Yervand Hakobyan, Yair Herishanu, José Ángel Hernández-Rivas, Tobias Herold, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Оlga B. Kalashnikova, Elżbieta Kalicińska, Arnon P. Kater, Sabina Kersting, Maya Koren-Michowitz, Jorge Labrador Gomez, Deepesh Lad, Luca Laurenti, Alberto Fresa, Mark-David Levin, Carlota Mayor Bastida, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet, Biljana Mihaljevic, Ivana Milosevic, Fatima Mirás, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Raquel Nunes, Jacopo Olivieri, Miguel Arturo Pavlovsky, Inga S. Piskunova, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Gianluigi Reda, Gian Matteo Rigolin, Amit Shrestha, Martin Šimkovič, Svetlana Smirnova, Martin Špaček, Paolo Sportoletti, Oana Stanca, Niki Stavroyianni, Doreen Te Raa, Kristina Tomic, Sanne Tonino, Livio Trentin, Ellen Van Der Spek, Michel van Gelder, Marzia Varettoni, Andrea Visentin, Candida Vitale, Vojin Vukovic, Ewa Wasik-Szczepanek, Tomasz Wróbel, Lucrecia Yanez San Segundo, Mohamed A Yassin, Marta Coscia, Alessandro Rambaldi, Emili Montserrat, Robin Foà, Antonio Cuneo, Marc Carrier, Paolo Ghia, Kostas Stamatopoulos

Blood (2022) 140 (Supplement 1): 2772–2775.

https://doi.org/10.1182/blood-2022-169909

Published: 2022

Journal Articles

Predictive and Prognostic Molecular Biomarkers in Familial Chronic Lymphocytic Leukemia: A Pilot Monocentric Study

Giulia Benintende, Idanna Innocenti, Alberto Fresa, Francesco Autore, Annamaria Tomasso, Florenzia Vuono, Luca Stirparo, Antonio Mosca, Dimitar G Efremov, Andrea Bacigalupo, Luca Laurenti

Blood (2022) 140 (Supplement 1): 7018–7019.

https://doi.org/10.1182/blood-2022-169897

Published: 2022

NARROW

Real-Life Multicentre Study on 547 Patients Affected By Waldenstrom Macroglobulinemia Treated with Chemo-Immunotherapy: Which Is the Best and Most Used First-Line Treatment?

Reappearance of CXCR4 dim /CD5 bright Proliferative Fraction Associates with BTK Mutations and Anticipates Progression in Ibrutinib-Treated CLL

Impact of COVID-19 in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Possible Role of the Association to Anti-CD20 Antibody? a Multicentre Seifem Study

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Ibrutinib As First Line Therapy in Chronic Lymphocytic Leukemia Patients over 80 Years Old: A Retrospective Real-Life Multicenter Italian Cohort

An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients into Novel Categories with Different Risk of Early Treatment

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Kinetics of Lymphocytosis during First-Line Treatment with BTK Covalent Inhibitors in Chronic Lymphocytic Leukemia Patients: An Italian Multicenter Experience of Real Life

Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study

Prevention of CINV in Patients with Multiple Myeloma or Lymphoma Undergoing Hematopoietic Stem Cell Transplantation: NEPA Versus Ondansetron. a Monocentric Real-Life Experience

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

CXCR4 Loss Reduces the Local Growth of Richter Syndrome Murine and Patient-Derived Xenograft Models and Impairs BCR and VLA-4 Activation

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo

Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Predictive and Prognostic Molecular Biomarkers in Familial Chronic Lymphocytic Leukemia: A Pilot Monocentric Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only